CG Labz
Peptide Library / Metabolic / Weight Management

Mazdutide

GLP-1/Glucagon Dual Agonist

Mazdutide Research Protocol

Complete Research Guide 4 min read1 peer-reviewed references

Quickstart Overview

Mazdutide (IBI362 / LY3305677) is a GLP-1 and glucagon receptor dual agonist based on the oxyntomodulin backbone. It is studied for weight reduction and reduction of hepatic fat, combining appetite suppression with increased energy expenditure.

Reconstitution
Add 2.0 mL bacteriostatic water to a 10 mg vial → 5 mg/mL
Measuring Reference
At 5 mg/mL: 1 mg = 0.2 mL = 20 units
Frequency
Once weekly
Half-life
~once-weekly
Route (studies)
Subcutaneous
Class
GLP-1 / glucagon dual agonist

Scientific Data

Molecular Formula
—
Molecular Weight
—
Sequence
IBI362 / LY3305677
Sequence Length
5
CAS
Research compound
Peptide Family
Dual incretin
Half-life
Refer to published literature
Solubility
Bacteriostatic water, sterile saline
Storage
Lyophilized: -20°C. Reconstituted: 2–8°C, use within 2–4 weeks.
Appearance
White lyophilized powder
Standard: 10 mg vial · 2 mL diluent

Dosing & Reconstitution Guide

Interactive Reconstitution
Adjust vial size, diluent and target dose. Results update live.
Full Precision Calculator →
Concentration
5.00 mg/mL
Draw Volume
0.200 mL
Syringe Units
20.0 U
Doses / Vial
10

Units assume a U-100 insulin syringe (100 units = 1 mL). Glucagon-arm agonists can raise heart rate; titrate conservatively.

Frequency: Once weekly

Reconstitution Steps

  1. 1Allow the lyophilized vial and bacteriostatic water to reach room temperature (~15 min).
  2. 2Swab both vial stoppers with a fresh 70% isopropyl alcohol pad and let them dry.
  3. 3Draw 2.0 mL of bacteriostatic water into a mixing syringe.
  4. 4Insert at an angle and let the water run slowly down the glass wall — never directly onto the powder.
  5. 5Gently swirl (do not shake) until the solution is completely clear.
  6. 6Label with date and concentration (mg/mL) and refrigerate at 2–8 °C immediately.

Supplies Needed

Planning example for a 20-week protocol at approximately 1000 mcg per day.

Peptide (10 mg vials)
Estimate vials from total mass: 1000 mcg/day × 140 days.
Bacteriostatic Water
One 10–30 mL vial typically covers a full cycle.
Insulin Syringes (U-100)
One per administration (29–31 G, 0.3–0.5 mL).
Alcohol Swabs
Two per administration (vial + site).
Sharps Container
Required for safe disposal.

Protocol Overview

Goal
Model GLP-1 + glucagon dual-agonist effects on weight and hepatic fat.
Schedule
Weekly, titrated.
Dose Range
Per titration schedule.

Dosing Protocol

Weeks 1–4
Low starting dose weekly
Titration
Increase every 4 weeks as tolerated
Maintenance
Target dose per response
Frequency
Once weekly
Timing
Same day weekly
Route
Subcutaneous

Storage Instructions

Lyophilized
−20 °C long term (18–24 months); stable at room temperature for short transit.
Reconstituted
2–8 °C refrigerated; use within 4 weeks.
Light
Protect from direct light; keep in the original carton.
Freeze/Thaw
Avoid repeat freeze–thaw cycles after reconstitution.

Important Notes

  • Monitor resting heart rate (glucagon-receptor activity).
  • Shares the incretin boxed-warning class.
  • Titrate gradually to manage GI effects.

How This Works

Mazdutide activates GLP-1 receptors (satiety, glucose-dependent insulin secretion, delayed gastric emptying) and glucagon receptors (increased energy expenditure and hepatic lipid oxidation). The glucagon arm adds a thermogenic component to appetite suppression, and an acyl chain enables once-weekly albumin-bound dosing.

Potential Benefits & Side Effects

Reported in research
  • Dose-dependent weight loss in Phase 2 trials
  • Reduced hepatic fat and improved lipid markers
  • Improved glycemic control
  • Appetite suppression plus increased energy expenditure
Possible considerations
  • Nausea, diarrhoea and GI effects (dose-dependent)
  • Transient heart-rate increase
  • Injection-site reactions
  • Long-term safety still under study

Lifestyle Factors

  • Adequate hydration and 7–9 h of sleep are standard controls in most research protocols.
  • Consistent dose timing improves the reliability of any self-tracked endpoints.
  • Maintain a clean, sterile workflow for every draw to avoid contamination.

Injection Technique

  1. 1Wash hands, then prep the vial top and the target site with separate alcohol swabs.
  2. 2Pinch a subcutaneous skin fold (abdomen, ~2 inches from the navel) and insert at 45–90°.
  3. 3Depress the plunger slowly over 3–5 seconds, hold 5 seconds, then withdraw.
  4. 4Rotate sites each administration and dispose of the syringe in a sharps container.

Frequently Asked Questions

Third-party HPLC testing

CG Labz Verified Batches

No published batches yet.

Research Disclaimer

All compounds are supplied strictly for laboratory research. Dosing figures below summarize ranges reported in published preclinical and clinical literature for reference purposes only. CG Labz does not provide medical advice or individualized dosing recommendations.

Peer-reviewed literature

References

  1. [1] The Lancet Diabetes & Endocrinology
    Ji L. et al. Mazdutide in Chinese adults with overweight or obesity.
    View Source